BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OrthoMimetics Reaches Patient Recruitment Milestone In Key European Clinical Study


9/14/2009 2:50:59 PM

Orthomimetics, the UK based regenerative medicine company has reported treatment of the tenth patient in a clinical study for Chondromimetic, a dual-layered implant for the repair of damaged cartilage and bone.

The single-centre study is being conducted under the supervision of world-renowned surgeon Professor Laszlo Hangody and is evaluating the safety and efficacy of Chondromimetic using multiple outcome variables.

Ten patients are enrolled in phase one of the clinical study and early MRI results look promising. The second phase of the study will evaluate the new Chondromimetic Instrumentation System for arthroscopic delivery of the implant. It is envisaged this new minimally invasive approach will make the surgical procedure quicker and easier and potentially reduce the time that patients must remain in hospital.

Building on this clinical data, Orthomimetics is hoping to expand its clinical research programme to a further 10 sites in Europe with the aim of recruiting a total of 200 patients who will be collected in a Clinical Register to further validate the technique and patient benefits.

Commenting on the trial, Andrew Lynn, CEO of Orthomimetics said: “We are extremely pleased to report the trial has been conducted to the schedule we set out and that these early outcomes are encouraging. We look forward to building on this progress to establish a set of high-quality clinical data to support the long-term efficacy of Chondromimetic and our commercial efforts.”

Orthomimetics Limited is a medical technology company that specialises in the design, development, and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: www.orthomimetics.com or contact Katherine Webster: info@orthomimetics.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES